QuVa Pharma, a new company that intends to stake a position in the rapidly changing sterile compounding market, has added a second registered compounding facility with its acquisition of Temple, TX-based Unique Pharmaceuticals. Qu Va was formed in August with a capital infusion from Bain Capital and already has a 503B registered facility in Sugar Land, TX. The compounding pharmacy company says it intends to focus on producing for hospitals sterile drugs that are in short supply. QuVa has jumped into the market at a time when the FDA has assumed more oversight of the compounding industry and required many of the pharmacies to recall products because of questions over sterility. The FDA started the 503B registration program for compounding pharmacies last year as part of the Drug Quality and Security Act. The new requirements were put in place after an outbreak of fungal meningitis that was tracked back to unsterile conditions at the compounding facility where it was produced. Release | More